Ignyta, Inc. RXDX today announced the exclusive license of
worldwide rights relating to Eli Lilly and Company's taladegib oncology
development program in exchange for an upfront payment of $2.0 million
in cash and the issuance to Lilly of approximately 1.2 million shares of
Ignyta's common stock. Taladegib is a potent, orally bioavailable small
molecule hedgehog/smoothened antagonist that has achieved clinical
proof-of-concept and a recommended Phase 2 dose based on results from
prior clinical studies. Ignyta also licensed exclusive worldwide rights
to the topical formulation of taladegib, which is a late preclinical
program being developed for the potential treatment of patients with
superficial and nodular basal cell carcinoma.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in